Teitur Trophics ApS become part of Incuba Skejby
We are very happy to become a part of the great innovative environment at Incuba Skejby, where we are able to develop and grow in our new offices and laboratories. Read more on the…
Read moreNews
Teitur Trophics has been nominated for EY Entrepreneur of The Year – Life Sciences
The team at Teitur are extremely honoured to have been nominated for EY Entrepreneur of The Year – Life Sciences. The nomination recognizes the development the company has gone through since starting in 2020.…
Read moreTeitur Trophics has been nominated for European Lifestars Award – Series A: Finance raise of the year
We are excited to be nominated for European Lifestars Award – Series A: Finance raise of the year. The nomination is a testament to the incredible team at Teitur Trophics and our ambition and…
Read moreTeitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases
-
Financing co-led by Sunstone Life Science Ventures and Sound Bioventures with participation from Industrifonden, Innovestor’s Life Science Fund and P53 Invest
-
Discovery of a novel mechanism with the potential to prevent the death of neurons in neurodegenerative diseases
-
First-in-Class, lead drug candidate advances into clinical development in a Phase 1b study
Aarhus, Denmark March 14th, 2023: Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases, today announces the completion of a €28M Series A financing. The…
Read moreTeitur Trophics receives Innobooster grant to develop candidate towards IND
Teitur is happy to have secured funding from the Innobooster grant from Innovation Fund Denmark. The grant will allow the company to finalize studies to nominate a candidate for IND enabling studies
Read moreTeitur Trophics closes convertible loan from Sunstone
Teitur today announces the successful closing of a €400.000 convertible loan from Sunstone to advance the preclinical program targeting neurodegenerative diseases.
Read moreTeitur Trophics receives Innobooster grant from Innovation Fund Denmark for advancing HD program
Teitur is happy to have secured funding from the Innobooster grant from Innovation Fund Denmark. The grant will enable the company to advance the innovative peptide project for treating patients suffering from Huntington’s Disease.
Read moreTeitur Trophics joins the BII Creation House program
The pharma company Teitur Trophics that targets neurodegenerative diseases has joined the BII Creation House program. As part of the Creation House program, Teitur Trophics will have access to a global network of life…
Read more